Comparison of losartan and captopril on heart failure–related outcomes and symptoms from the losartan heart failure survival study (ELITE II)
- 31 July 2005
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 150 (1), 123-131
- https://doi.org/10.1016/j.ahj.2004.10.035
Abstract
Blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors improves outcomes and symptoms in patients with heart failure (HF). We compared effects of losartan to captopril on mortality, morbidity, and functional status for patients in the ELITE II study. A total of 3152 patients, aged 60 years or older, with New York Heart Association (NYHA) classes II to IV HF and ejection fraction ≤40% were assigned to receive losartan 50 mg once daily or captopril 50 mg 3 times daily. Outcome measures included all-cause and HF-related mortality, hospitalizations, and discontinuations; change in NYHA class; and quality of life (QoL). HF-related outcomes were not significantly different between therapies. Similar improvements from baseline (P < .01) in NYHA class were observed within both treatment groups. Among 1856 QoL participants, 1343 patients survived at least 1 year; the QoL for 1-year survivors improved in both treatment groups (P < .001 vs baseline) and did not differ between groups. In ELITE II, the effects of losartan on HF-related outcomes, NYHA class, and QoL were not superior to those of captopril. Although angiotensin-converting enzyme inhibitors remain the treatment of choice for patients with HF, the similarity of the findings in the present analysis supports a role for angiotensin-receptor antagonists in this patient population.Keywords
This publication has 10 references indexed in Scilit:
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialThe Lancet, 2003
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialThe Lancet, 2003
- Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trialThe Lancet, 2002
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE IIThe Lancet, 2000
- Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: Rationale, design, and baseline characteristics of patients in the losartan heart failure survival study-ELITE IIJournal of Cardiac Failure, 1999
- Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)The Lancet, 1997
- The Management of Chronic Heart FailureNew England Journal of Medicine, 1996
- EuroQol: the current state of playHealth Policy, 1996
- Guidelines for the Evaluation and Management of Heart FailureCirculation, 1995